-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK’S LIPFENDRA® (ENLICITIDE) IS THE FIRST AND ONLY ONCE-DAILY ORAL PCSK9 INHIBITOR APPROVED BY THE U.S. FDA TO REDUCE LDL-C IN ADULTS WITH HYPERCHOLESTEROLEMIA

路透·07/16/2026 10:45:00

登錄查看新聞詳情